<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01053481</url>
  </required_header>
  <id_info>
    <org_study_id>2009-04-07-Ca41</org_study_id>
    <nct_id>NCT01053481</nct_id>
  </id_info>
  <brief_title>Using Ca-41 Methodology to Assess the Impact of Different Vitamin D Supplementation Levels on Postmenopausal Bone Health</brief_title>
  <official_title>Using Ca-41 Methodology to Assess the Impact of Different Vitamin D Supplementation Levels on Postmenopausal Bone Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Federal Institute of Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DSM Nutritional Products, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Swiss Federal Institute of Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether increasing levels of serum 25(OH)Vitamin D
      as achieved by oral supplementation higher than the current recommendations are associated
      with a less negative bone calcium balance in post-menopausal Swiss women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a substudy - not related to the vitamin D intervention - spot and 24 h urine samples are
      compared with regard to the assessment of iodine status in Swiss post-menopausal women.

      In an short subsequent study using five of the subjects who participated in the original
      trial, the effect of a 40 d-exercise program (rebounding on a trampoline) on Ca-41 excretion
      will be observed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>urinary Ca-41/Ca-40 ratio</measure>
    <time_frame>March 2010 to January 2011</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>biomarkers of bone metabolism</measure>
    <time_frame>March 2010 to January 2011</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urinary iodine</measure>
    <time_frame>August 2009 to December 2010</time_frame>
    <description>Comparison of spot and 24 h urine samples for the assessment of iodine status (substudy, not related to vitamin D intervention)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Osteopenia</condition>
  <arm_group>
    <arm_group_label>Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D supplement</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>vitamin D</intervention_name>
    <description>Vitamin D supplement</description>
    <arm_group_label>Vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>exercise program (rebounding on a trampoline)</intervention_name>
    <description>40 days at 30 min/d</description>
    <arm_group_label>Vitamin D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  apparently healthy women, at least 5 years post-menopausal

          -  BMI 18-30

          -  no HRT

          -  no regular intake of Ca or vit D supplements

          -  wiling and able to give written informed consent and to understand, participate and
             comply with study requirements

          -  non-smokers

          -  no long travels (&gt;3 wk) planned within study period

        Exclusion Criteria:

          -  diseases that predispose to osteoporosis

          -  history of fragility fractures

          -  currently on a weight reduction program

          -  excessive physical activity

          -  diseases influencing calcium metabolism (thyroid, parathyroid, adrenal disorders etc.)

          -  regular intake of medication affecting calcium metabolism

          -  osteoporosis (T-score below -2.5)

          -  history of psychological illness likely to interfere with the subject's ability to
             understand the requirements of the study

          -  participation in concurrent studies
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael B Zimmermann, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Human Nutrition Laboratory, Institute of Food, Nutrition and Health, ETH Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8092</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Denk E, Hillegonds D, Hurrell RF, Vogel J, Fattinger K, HÃ¤uselmann HJ, Kraenzlin M, Walczyk T. Evaluation of 41calcium as a new approach to assess changes in bone metabolism: effect of a bisphosphonate intervention in postmenopausal women with low bone mass. J Bone Miner Res. 2007 Oct;22(10):1518-25.</citation>
    <PMID>17576167</PMID>
  </reference>
  <reference>
    <citation>Denk E, Hillegonds D, Vogel J, Synal A, Geppert C, Wendt K, Fattinger K, Hennessy C, Berglund M, Hurrell RF, Walczyk T. Labeling the human skeleton with 41Ca to assess changes in bone calcium metabolism. Anal Bioanal Chem. 2006 Nov;386(6):1587-602. Epub 2006 Oct 11.</citation>
    <PMID>17033771</PMID>
  </reference>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2010</study_first_submitted>
  <study_first_submitted_qc>January 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2010</study_first_posted>
  <last_update_submitted>November 21, 2013</last_update_submitted>
  <last_update_submitted_qc>November 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Swiss Federal Institute of Technology</investigator_affiliation>
    <investigator_full_name>Prof. Michael B. Zimmermann</investigator_full_name>
    <investigator_title>Prof. Dr. med</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

